nach oben

Journal of Gastrointestinal Surgery

Erschienen in:

01.08.2007 | Review Article

Surgical Therapy for Colorectal Metastases to the Liver

verfasst von: Timothy M. Pawlik, Michael A. Choti

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55% of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of colorectal liver metastases represents the only chance at potential cure, and long-term survival can be achieved in 35 to 58% of patients after resection. The goal of hepatic resection should be to resect all metastases with negative histologic margins while preserving sufficient functional hepatic parenchyma. In patients with extensive metastatic disease who would otherwise be unresectable, ablative approaches can be used instead of or combined with hepatic resection. The use of portal vein embolization and preoperative chemotherapy may also expand the population of patients who are candidates for surgical treatment. Despite these advances, many patients still experience a recurrence after hepatic resection. More active systemic chemotherapy agents are now available and are being increasingly employed as adjuvant therapy either before or after surgery. Modern treatment of colorectal liver metastasis requires a multidisciplinary approach in an effort to increase the number of patients who may benefit from surgical treatment of colorectal cancer liver metastasis.

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.PubMed

Steele G, Jr., Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989;210:127–138.PubMed

Cady B, Monson DO, Swinton NW. Survival of patients after colonic resection for carcinoma with simultaneous liver metastases. Surg Gynecol Obstet 1970;131:697–700.PubMed

Blumgart LH, Allison DJ. Resection and embolization in the management of secondary hepatic tumors. World J Surg 1982;6:32–45.PubMed

Jatzko G, Wette V, Muller M, Lisborg P, Klimpfinger M, Denk H. Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorectal Dis 1991;6:111–114.PubMed

Finlay IG, McArdle CS. Occult hepatic metastases in colorectal carcinoma. Br J Surg 1986;73:732–735.PubMed

Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59–71.PubMed

Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 2003;12: 165–192, xi.PubMed

Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991;110:13–29.PubMed

10.

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–318; discussion 318–321.PubMed

11.

Jaffe BM, Donegan WL, Watson F, Spratt JS, Jr. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 1968;127:1–11.PubMed

12.

Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969;23:198–202.PubMed

13.

de Brauw LM, van de Velde CJ, Bouwhuis-Hoogerwerf ML, Zwaveling A. Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 1987;34:81–86.PubMed

14.

Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981;141:586–589.PubMed

15.

Goslin R, Steele G, Jr., Zamcheck N, Mayer R, MacIntyre J. Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982;25:749–754.PubMed

16.

[No authors listed]. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-analysis Project. J Clin Oncol 1992;10:896–903.

17.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–914.PubMed

18.

de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808–815.PubMed

19.

Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–1047.PubMed

20.

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.PubMed

21.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.PubMed

22.

Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–1418.PubMed

23.

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352: 1407–1412.PubMed

24.

Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059–2069.PubMed

25.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.PubMed

26.

Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201–1208.PubMed

27.

Moertel CG, Gunderson LL, Mailliard JA, McKenna PJ, Martenson JA, Jr., Burch PA, Cha SS. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol 1994;12:21–27.PubMed

28.

Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–825; discussion 825–817.PubMed

29.

Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241–1246.PubMed

30.

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–766.PubMed

31.

Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D, et al. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 1988;31:1–4.PubMed

32.

Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984;119:647–651.PubMed

33.

Schlag P, Hohenberger P, Herfarth C. Resection of liver metastases in colorectal cancer—competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 1990;16:360–365.PubMed

34.

Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, Starzl TE. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994;116:703–710; discussion 710–701.PubMed

35.

Jenkins LT, Millikan KW, Bines SD, Staren ED, Doolas A. Hepatic resection for metastatic colorectal cancer. Am Surg 1997;63:605–610.PubMed

36.

Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997;132:505–510; discussion 511.PubMed

37.

Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med 2005;56: 139–156.PubMed

38.

Thompson HH, Tompkins RK, Longmire WP, Jr. Major hepatic resection. A 25-year experience. Ann Surg 1983;197:375–388.PubMed

39.

Fortner JG, Kim DK, Maclean BJ, Barrett MK, Iwatsuki S, Turnbull AD, Howland WS, Beattie EJ, Jr. Major hepatic resection for neoplasia: personal experience in 108 patients. Ann Surg 1978;188:363–371.PubMed

40.

Tsao JI, Loftus JP, Nagorney DM, Adson MA, Ilstrup DM. Trends in morbidity and mortality of hepatic resection for malignancy. A matched comparative analysis. Ann Surg 1994;220:199–205.PubMed

41.

Taylor M, Forster J, Langer B, Taylor BR, Greig PD, Mahut C. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 1997;173:467–471.PubMed

42.

Bozzetti F, Gennari L, Regalia E, Bignami P, Montalto F, Mazzaferro V, Doci R. Morbidity and mortality after surgical resection of liver tumors. Analysis of 229 cases. Hepatogastroenterology 1992;39:237–241.PubMed

43.

Capussotti L, Polastri R. Operative risks of major hepatic resections. Hepatogastroenterology 1998;45:184–190.PubMed

44.

Sitzmann JV, Greene PS. Perioperative predictors of morbidity following hepatic resection for neoplasm. A multivariate analysis of a single surgeon experience with 105 patients. Ann Surg 1994; 219:13–17.PubMed

45.

Mentha G, Huber O, Robert J, Klopfenstein C, Egeli R, Rohner A. Elective hepatic resection in the elderly. Br J Surg 1992;79:557–559.PubMed

46.

Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38–46.PubMed

47.

Gagner M, Franco D, Vons C, Smadja C, Rossi RL, Braasch JW. Analysis of morbidity and mortality rates in right hepatectomy with the preoperative APACHE II score. Surgery 1991;110:487–492.PubMed

48.

Davis SD. CT evaluation for pulmonary metastases in patients with extrathoracic malignancy. Radiology 1991;180:1–12.PubMed

49.

Kronawitter U, Kemeny NE, Heelan R, Fata F, Fong Y. Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma. Cancer 1999;86:229–235.PubMed

50.

Povoski SP, Fong Y, Sgouros SC, Kemeny NE, Downey RJ, Blumgart LH. Role of chest CT in patients with negative chest x-rays referred for hepatic colorectal metastases. Ann Surg Oncol 1998;5:9–15.PubMed

51.

Nelson RC, Chezmar JL, Sugarbaker PH, Bernardino ME. Hepatic tumors: comparison of CT during arterial portography, delayed CT, and MR imaging for preoperative evaluation. Radiology 1989;172:27–34.PubMed

52.

Heiken JP, Weyman PJ, Lee JK, Balfe DM, Picus D, Brunt EM, Flye MW. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989;171:47–51.PubMed

53.

Soyer P, Levesque M, Elias D, Zeitoun G, Roche A. Preoperative assessment of resectability of hepatic metastases from colonic carcinoma: CT portography vs sonography and dynamic CT. AJR Am J Roentgenol Am J Roentgenol 1992;159:741–744.

54.

Barakos JA, Goldberg HI, Brown JJ, Gilbert TJ. Comparison of computed tomography and magnetic resonance imaging in the evaluation of focal hepatic lesions. Gastrointest Radiol 1990; 15:93–101.PubMed

55.

Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF, Davidson BR. Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 2004;91:1361–1369.PubMed

56.

Kamel IR, Choti MA, Horton KM, Braga HJ, Birnbaum BA, Fishman EK, Thompson RE, Bluemke DA. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology 2003; 227:752–757.PubMed

57.

Kuszyk BS, Bluemke DA, Urban BA, Choti MA, Hruban RH, Sitzmann JV, Fishman EK. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings. AJR Am J Roentgenol Am J Roentgenol 1996;166:91–95.

58.

Kondo H, Kanematsu M, Hoshi H, Murakami T, Kim T, Hori M, Matsuo M, Nakamura H. Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT. AJR Am J Roentgenol Am J Roentgenol 2000;174:947–954.

59.

Semelka RC, Worawattanakul S, Kelekis NL, John G, Woosley JT, Graham M, Cance WG. Liver lesion detection, characterization, and effect on patient management: comparison of single-phase spiral CT and current MR techniques. J Magn Reson Imaging 1997;7:1040–1047.PubMed

60.

Soyer P, Bluemke DA, Hruban RH, Sitzmann JV, Fishman EK. Hepatic metastases from colorectal cancer: detection and false-positive findings with helical CT during arterial portography. Radiology 1994;193:71–74.PubMed

61.

Bluemke DA, Soyer P, Fishman EK. Nontumorous low-attenuation defects in the liver on helical CT during arterial portography: frequency, location, and appearance. AJR Am J Roentgenol Am J Roentgenol 1995;164:1141–1145.

62.

Soyer P, Bluemke DA, Fishman EK. CT during arterial portography for the preoperative evaluation of hepatic tumors: how, when, and why? AJR Am J Roentgenol Am J Roentgenol 1994;163:1325–1331.

63.

Semelka RC, Schlund JF, Molina PL, Willms AB, Kahlenberg M, Mauro MA, Weeks SM, Cance WG. Malignant liver lesions: comparison of spiral CT arterial portography and MR imaging for diagnostic accuracy, cost, and effect on patient management. J Magn Reson Imaging 1996;6:39–43.PubMed

64.

Bluemke DA, Soyer PA, Chan BW, Bliss DF, Calhoun PS, Fishman EK. Spiral CT during arterial portography: technique and applications. Radiographics 1995;15:623–637; discussion 638–629.PubMed

65.

Oudkerk M, van den Heuvel AG, Wielopolski PA, Schmitz PI, Borel Rinkes IH, Wiggers T. Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology 1997;203:449–456.PubMed

66.

van Etten B, van der Sijp J, Kruyt R, Oudkerk M, van der Holt B, Wiggers T. Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases. Eur J Surg Oncol 2002;28:645–651.PubMed

67.

Yamashita Y, Hatanaka Y, Yamamoto H, Arakawa A, Matsukawa T, Miyazaki T, Takahashi M. Differential diagnosis of focal liver lesions: role of spin-echo and contrast-enhanced dynamic MR imaging. Radiology 1994;193:59–65.PubMed

68.

Peterson MS, Baron RL, Murakami T. Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 1996;201:337–345.PubMed

69.

Low RN, Francis IR, Herfkens RJ, Jeffrey RB, Jr., Glazer GM, Foo TK, Shimakawa A, Pelc NJ. Fast multiplanar spoiled gradient-recalled imaging of the liver: pulse sequence optimization and comparison with spin-echo MR imaging. AJR Am J Roentgenol Am J Roentgenol 1993;160:501–509.

70.

Larson RE, Semelka RC, Bagley AS, Molina PL, Brown ED, Lee JK. Hypervascular malignant liver lesions: comparison of various MR imaging pulse sequences and dynamic CT. Radiology 1994; 192:393–399.PubMed

71.

Winter TC, III, Freeny PC, Nghiem HV, Mack LA, Patten RM, Thomas CR, Jr., Elliott S. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions. AJR Am J Roentgenol Am J Roentgenol 1993;161:1191–1198.

72.

Ros PR, Freeny PC, Harms SE, Seltzer SE, Davis PL, Chan TW, Stillman AE, Muroff LR, Runge VM, Nissenbaum MA, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481–488.PubMed

73.

Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995;196:471–478.PubMed

74.

Sica GT, Ji H, Ros PR. CT and MR imaging of hepatic metastases. AJR Am J Roentgenol Am J Roentgenol 2000; 174:691–698.

75.

Matsuo M, Kanematsu M, Itoh K, Ito K, Maetani Y, Kondo H, Kako N, Matsunaga N, Hoshi H, Shiraishi J. Detection of malignant hepatic tumors: comparison of gadolinium-and ferumoxide-enhanced MR imaging. AJR Am J Roentgenol Am J Roentgenol 2001;177:637–643.

76.

Vogl TJ, Hammerstingl R, Schwarz W, Kummel S, Muller PK, Balzer T, Lauten MJ, Balzer JO, Mack MG, Schimpfky C, Schrem H, Bechstein WO, Neuhaus P, Felix R. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest Radiol 1996;31:696–708.PubMed

77.

Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20:4453–4458.PubMed

78.

Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, Chapman WC, Pinson CW. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–26.PubMed

79.

Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, Spaulding MB. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755–760.PubMed

80.

Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369–1379.PubMed

81.

Schoder H, Erdi YE, Larson SM, Yeung HW. PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003;30:1419–1437.PubMed

82.

Larson SM, Schoder H, Yeung H. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. Cancer J 2004;10:243–250.PubMedCrossRef

83.

Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:1027–1034; discussion 1035–1026.PubMed

84.

Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575–581.PubMed

85.

Yeung HW, Schoder H, Smith A, Gonen M, Larson SM. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-d-glucose–positron emission tomography studies in cancer patients. Mol Imaging Biol 2005;7:229–235.PubMed

86.

Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748–756.PubMed

87.

Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002;29:915–921.PubMed

88.

Halkar RK, Toro JR, Lim EH, Staley CA, Grafton ST, Garcia EV, Hoffman J. Role of FDG-PET in the pre-operative evaluation of surgical resection of hepatic metastases from colorectal cancer. Clin Positron Imaging 1999;2:335.PubMed

89.

Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart S, Choti MA. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 2006;141:1220–1226.PubMed

90.

Guillem JG, Puig-La Calle J, Jr., Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18–24.PubMed

91.

Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, Minsky BD, Saltz L, Wong WD, Larson S. Sequential preoperative fluorodeoxyglucose–positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 2004;199:1–7.PubMed

92.

Kokudo N, Imamura H, Sugawara Y, Sakamoto Y, Yamamoto J, Seki M, Makuuchi M. Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg 2004;11:84–91.PubMed

93.

Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000;7:643–650.PubMed

94.

Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999;189:291–299.PubMed

95.

Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, Bengmark S. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986;73:727–731.PubMed

96.

Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975–979; discussion 979–980.PubMed

97.

Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, Ducreux M, Baldeyrou P, Levasseur P. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998;66:214–218; discussion 218–219.PubMed

98.

Vauthey JN, Pawlik TM, Abdalla EK, Arens JF, Nemr RA, Wei SH, Kennamer DL, Ellis LM, Curley SA. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004;239: 722–730; discussion 730–722.PubMed

99.

Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675–680; discussion 680–671.PubMed

100.

Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001;88:165–175.PubMed

101.

Uesaka K, Nimura Y, Nagino M. Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion. Ann Surg 1996;223:77–83.PubMed

102.

Abdalla EK, Denys A, Chevalier P, Nemr RA, Vauthey JN. Total and segmental liver volume variations: implications for liver surgery. Surgery 2004;135:404–410.PubMed

103.

Nagino M, Nimura Y, Kamiya J, Kondo S, Uesaka K, Kin Y, Kutsuna Y, Hayakawa N, Yamamoto H. Right or left trisegment portal vein embolization before hepatic trisegmentectomy for hilar bile duct carcinoma. Surgery 1995;117:677–681.PubMed

104.

Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938–946.PubMed

105.

Harmon JW, Tang DG, Gordon TA, Bowman HM, Choti MA, Kaufman HS, Bender JS, Duncan MD, Magnuson TH, Lillemoe KD, Cameron JL. Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. Ann Surg 1999;230:404–411; discussion 411–403.PubMed

106.

Aloia TA, Zorzi D, Abdalla EK, Vauthey JN. Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg 2005;242:172–177.PubMed

107.

Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715–722, discussion 722–714.PubMed

108.

Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases. Surgery 1988;103:278–288.

109.

Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–1262.PubMed

110.

Ambiru S, Miyazaki M, Isono T, Ito H, Nakagawa K, Shimizu H, Kusashio K, Furuya S, Nakajima N. Hepatic resection for colorectal metastases: analysis of prognostic factors. Dis Colon Rectum 1999;42:632–639.PubMed

111.

Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg 2000;231:59–66.PubMed

112.

Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000;231:487–499.PubMed

113.

Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Analysis of preoperative prognostic factors for long-term survival after hepatic resection of liver metastasis of colorectal carcinoma. J Gastrointest Surg 2005;9:374–380.PubMed

114.

Domont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM, Brown TD, Zorzi D, Morat L, Pignon JP, Rashid A, Jaeck D, Sabatier L, Elias D, Tursz T, Soria JC, Vauthey JN. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 2005;23:3086–3093.PubMed

115.

Nitti D, Belluco C, Montesco MC, Bertorelle R, Da Pian PP, Fassina A, Ninfo V, Chieco-Bianchi L, Lise M. Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival. Eur J Cancer 1998;34:851–855.PubMed

116.

Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, Wolf P, Chenard-Neu MP, Jaeck D. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 2001;182:81–88.PubMed

117.

de Jong KP, Lont HE, Bijma AM, Brouwers MA, de Vries EG, van Veen ML, Marquet RL, Slooff MJ, Terpstra OT. The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology 1995;22:1263–1272.PubMed

118.

Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J, Kemeny N. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21:406–412.PubMed

119.

Smith DL, Soria JC, Morat L, Yang Q, Sabatier L, Liu DD, Nemr RA, Rashid A, Vauthey JN. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 2004;11:45–51.PubMed

120.

Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Kohne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001;27:80–87.PubMed

121.

De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998;28:971–979.PubMed

122.

Costa A, Doci R, Mochen C, Bignami P, Faranda A, Gennari L, Silvestrini R. Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol 1997;15:2008–2014.PubMed

123.

Nieveen van Dijkum EJ, de Wit LT, van Delden OM, Rauws EA, van Lanschot JJ, Obertop H, Gouma DJ. The efficacy of laparoscopic staging in patients with upper gastrointestinal tumors. Cancer 1997;79:1315–1319.PubMed

124.

John TG, Greig JD, Crosbie JL, Miles WF, Garden OJ. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann Surg 1994;220:711–719.PubMed

125.

Jarnagin WR, Conlon K, Bodniewicz J, Dougherty E, DeMatteo RP, Blumgart LH, Fong Y. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 2001;91:1121–1128.PubMed

126.

Rahusen FD, Cuesta MA, Borgstein PJ, Bleichrodt RP, Barkhof F, Doesburg T, Meijer S. Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. Ann Surg 1999;230:31–37.PubMed

127.

Figueras J, Valls C. The use of laparoscopic ultrasonography in the preoperative study of patients with colorectal liver metastases. Ann Surg 2000;232:721–723.PubMed

128.

Machi J, Isomoto H, Kurohiji T, Yamashita Y, Shirouzu K, Kakegawa T, Sigel B, Zaren HA, Sariego J. Accuracy of intraoperative ultrasonography in diagnosing liver metastasis from colorectal cancer: evaluation with postoperative follow-up results. World J Surg 1991;15:551–556; discussion 557.PubMed

129.

Barbot DJ, Marks JH, Feld RI, Liu JB, Rosato FE. Improved staging of liver tumors using laparoscopic intraoperative ultrasound. J Surg Oncol 1997;64:63–67.PubMed

130.

Rifkin MD, Rosato FE, Branch HM, Foster J, Yang SL, Barbot DJ, Marks GJ. Intraoperative ultrasound of the liver. An important adjunctive tool for decision making in the operating room. Ann Surg 1987;205:466–472.PubMed

131.

Solomon MJ, Stephen MS, Gallinger S, White GH. Does intraoperative hepatic ultrasonography change surgical decision making during liver resection? Am J Surg 1994;168:307–310.PubMed

132.

Gozzetti G, Mazziotti A, Bolondi L, Cavallari A, Grigioni W, Casanova P, Bellusci R, Villanacci V, Labo G. Intraoperative ultrasonography in surgery for liver tumors. Surgery 1986;99: 523–530.PubMed

133.

Staren ED, Gambla M, Deziel DJ, Velasco J, Saclarides TJ, Millikan K, Doolas A. Intraoperative ultrasound in the management of liver neoplasms. Am Surg 1997;63:591–596; discussion 596–597.PubMed

134.

Luck AJ, Maddern GJ. Intraoperative abdominal ultrasonography. Br J Surg 1999;86:5–16.PubMed

135.

Machi J, Sigel B, Zaren HA, Kurohiji T, Yamashita Y. Operative ultrasonography during hepatobiliary and pancreatic surgery. World J Surg 1993;17:640–645; discussion 645–646.PubMed

136.

Soyer P, Elias D, Zeitoun G, Roche A, Levesque M. Surgical treatment of hepatic metastases: impact of intraoperative sonography. AJR Am J Roentgenol Am J Roentgenol 1993;160: 511–514.

137.

Zacherl J, Scheuba C, Imhof M, Zacherl M, Langle F, Pokieser P, Wrba F, Wenzl E, Muhlbacher F, Jakesz R, Steininger R. Current value of intraoperative sonography during surgery for hepatic neoplasms. World J Surg 2002;26:550–554.PubMed

138.

Machi J, Sigel B. Operative ultrasound in general surgery. Am J Surg 1996;172:15–20.PubMed

139.

Yasui K, Shimizu Y. Surgical treatment for metastatic malignancies. Anatomical resection of liver metastasis: indications and outcomes. Int J Clin Oncol 2005;10:86–96.PubMed

140.

Yamamoto J, Saiura A, Koga R, Seki M, Ueno M, Oya M, Azekura K, Seto Y, Ohyama S, Fukunaga S, Yamaguchi T, Kokudo N, Makuuchi M, Muto T. Surgical treatment for metastatic malignancies. Nonanatomical resection of liver metastasis: indications and outcomes. Int J Clin Oncol 2005;10:97–102.PubMed

141.

DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 2000;4:178–184.PubMed

142.

Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Matsubara T, Takahashi T, Nakajima T, Muto T. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 2001;181:153–159.PubMed

143.

Kokudo N, Miki Y, Sugai S, Yanagisawa A, Kato Y, Sakamoto Y, Yamamoto J, Yamaguchi T, Muto T, Makuuchi M. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002;137:833–840.PubMed

144.

Cady B, Jenkins RL, Steele GD, Jr., Lewis WD, Stone MD, McDermott WV, Jessup JM, Bothe A, Lalor P, Lovett EJ, Lavin P, Linehan DC. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998;227:566–571.PubMed

145.

Shirabe K, Takenaka K, Gion T, Fujiwara Y, Shimada M, Yanaga K, Maeda T, Kajiyama K, Sugimachi K. Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin. Br J Surg 1997;84:1077–1080.PubMed

146.

Fuhrman GM, Curley SA, Hohn DC, Roh MS. Improved survival after resection of colorectal liver metastases. Ann Surg Oncol 1995;2:537–541.PubMed

147.

Steele G, Jr., Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991;9:1105–1112.PubMed

148.

Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996;131:322–329.PubMed

149.

Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North Am 1989;69:339–359.PubMed

150.

Nakamura S, Suzuki S, Konno H. Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J Hepatobiliary Pancreat Surg 1999;6:16–22.PubMed

151.

Bakalakos EA, Young DC, Martin EW, Jr. Radioimmunoguided surgery for patients with liver metastases secondary to colorectal cancer. Ann Surg Oncol 1998;5:590–594.PubMed

152.

Yasui K, Hirai T, Kato T, Torii A, Uesaka K, Morimoto T, Kodera Y, Yamamura Y, Kito T, Hamajima N. A new macroscopic classification predicts prognosis for patient with liver metastases from colorectal cancer. Ann Surg 1997;226:582–586.PubMed

153.

Jaeck D, Nakano H, Bachellier P, Inoue K, Weber JC, Oussoultzoglou E, Wolf P, Chenard-Neu MP. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002;9:430–438.PubMed

154.

Laurent C, Sa Cunha A, Rullier E, Smith D, Rullier A, Saric J. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 2004;198:884–891.PubMed

155.

Adam R, Vinet E. Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol 2004;15(Suppl 4):iv103–iv106.PubMed

156.

Togo S, Nagano Y, Masui H, Tanaka K, Miura Y, Morioka D, Endo I, Sekido H, Ike H, Shimada H. Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. Hepatogastroenterology 2005;52:913–919.PubMed

157.

Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777–785.PubMed

158.

Yang R, Kopecky KK, Rescorla FJ, Galliani CA, Wu EX, Grosfeld JL. Sonographic and computed tomography characteristics of liver ablation lesions induced by high-intensity focussed ultrasound. Invest Radiol 1993;28:796–801.PubMed

159.

Sibille A, Prat F, Chapelon JY, Abou el Fadil F, Henry L, Theillere Y, Ponchon T, Cathignol D. Extracorporeal ablation of liver tissue by high-intensity focused ultrasound. Oncology 1993;50:375–379.PubMedCrossRef

160.

Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, Eichler K, Woitaschek D, Zangos S. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003;229:457–464.PubMed

161.

Christophi C, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V. Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy. World J Surg 2004;28:987–994.PubMed

162.

Buscombe JR. Interventional nuclear medicine in hepatocellular carcinoma and other tumours. Nucl Med Commun 2002;23:837–841.PubMed

163.

Rhim H, Dodd GD, III. Radiofrequency thermal ablation of liver tumors. J Clin Ultrasound 1999;27:221–229.PubMed

164.

McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P, Browning PD. Hepatic ablation with use of radio-frequency electrocautery in the animal model. J Vasc Interv Radiol 1992;3:291–297.PubMedCrossRef

165.

Curley SA, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev 2004;23: 165–182.PubMed

166.

Curley SA, Davidson BS, Fleming RY, Izzo F, Stephens LC, Tinkey P, Cromeens D. Laparoscopically guided bipolar radiofrequency ablation of areas of porcine liver. Surg Endosc 1997;11:729–733.PubMed

167.

Machi J, Uchida S, Sumida K, Limm WM, Hundahl SA, Oishi AJ, Furumoto NL, Oishi RH. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 2001;5:477–489.PubMed

168.

Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 2003;10:52–58.PubMed

169.

Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999;230:1–8.PubMed

170.

Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol 2003;10:338–347.PubMed

171.

Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003;10: 1059–1069.PubMed

172.

Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7:593–600.PubMed

173.

Bilchik AJ, Wood TF, Allegra DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist 2001;6:24–33.PubMed

174.

Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242:158–171.PubMed

175.

de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol Am J Roentgenol 2000;175:1619–1625.

176.

Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 2001;13:149–158.PubMed

177.

Gillams AR. Thermal ablation of liver metastases. Abdom Imaging 2001;26:361–368.PubMed

178.

Shibata T, Niinobu T, Ogata N. Comparison of the effects of in-vivo thermal ablation of pig liver by microwave and radiofrequency coagulation. J Hepatobiliary Pancreat Surg 2000;7: 592–598.PubMed

179.

Shock SA, Meredith K, Warner TF, Sampson LA, Wright AS, Winter TC, III, Mahvi DM, Fine JP, Lee FT, Jr. Microwave ablation with loop antenna: in vivo porcine liver model. Radiology 2004;231:143–149.PubMed

180.

Sato M, Watanabe Y, Kashu Y, Nakata T, Hamada Y, Kawachi K. Sequential percutaneous microwave coagulation therapy for liver tumor. Am J Surg 1998;175:322–324.PubMed

181.

Matsukawa T, Yamashita Y, Arakawa A, Nishiharu T, Urata J, Murakami R, Takahashi M, Yoshimatsu S. Percutaneous microwave coagulation therapy in liver tumors. A 3-year experience. Acta Radiol 1997;38:410–415.PubMedCrossRef

182.

Seki T, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, Nishimura A, Yamashiki N, Inoue K. Percutaneous microwave coagulation therapy for solitary metastatic liver tumors from colorectal cancer: a pilot clinical study. Am J Gastroenterol 1999;94:322–327.PubMed

183.

Rothstein KD. Percutaneous microwave coagulation therapy: another option for the treatment of hepatic metastases. Am J Gastroenterol 1999;94:299–300.PubMed

184.

Skinner MG, Iizuka MN, Kolios MC, Sherar MD. A theoretical comparison of energy sources—microwave, ultrasound and laser—for interstitial thermal therapy. Phys Med Biol 1998;43:3535–3547.PubMed

185.

Colucci G, Maiello E, Leo S, Giuliani F, Pedicini A, Pezzella G, Valori V, Galetta D, Contillo A, Prete F. Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell’ Italia Meridionale (GOIM). Anticancer Res 1994;14:2157–2162.PubMed

186.

Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303–1311.PubMed

187.

Buroker TR, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH, Jr. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14–20.PubMed

188.

[No authors listed]. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998;16:301–308.

189.

Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873–14878.PubMed

190.

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–147.PubMed

191.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229–237.PubMed

192.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–65.PubMed

193.

Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005;23:4853–4855.PubMed

194.

Gordon MS, Margolin K, Talpaz M, Sledge GW, Jr., Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843–850.PubMed

195.

Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32S–40S.PubMed

196.

Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637–4642.PubMed

197.

Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994–1003.PubMed

198.

Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D’Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904–914.PubMed

199.

Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909–916.PubMed

200.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–345.PubMed

201.

Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509–520; discussion 520–502.PubMed

202.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–657; discussion 657–648.PubMed

203.

Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347–353.PubMed

204.

Rivoire M, De Cian F, Meeus P, Negrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95:2283–2292.PubMed

205.

Fowler WC, Eisenberg BL, Hoffman JP. Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 1992;51:122–125.PubMed

206.

Wein A, Riedel C, Kockerling F, Martus P, Baum U, Brueckl WM, Reck T, Ott R, Hansler J, Bernatik T, Becker D, Schneider T, Hohenberger W, Hahn EG. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001;12:1721–1727.PubMed

207.

Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–1061; discussion 1061–1054.PubMed

208.

Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003;90:963–969.PubMed

209.

Weber JC, Navarra G, Jiao LR, Nicholls JP, Jensen SL, Habib NA. New technique for liver resection using heat coagulative necrosis. Ann Surg 2002;236:560–563.PubMed

210.

Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003;7:1082–1088.PubMed

211.

Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109–115; discussion 116–107.PubMed

212.

Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460–466.PubMed

213.

Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845–853.PubMed

214.

Bonetti A. Hepatic artery infusion for liver metastases from colorectal cancer. Lancet 2003;361:358–359.PubMed

215.

Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Roullet Audy JC, Gallot D, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112–1118.PubMed

216.

Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, Botet J, Oderman P, Murray P. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992;69:327–334.PubMed

217.

Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson ER, O’Dwyer PJ, Benson AB, III. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol 2002;20:1499–1505.PubMed

218.

[No authors listed]. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-analysis Group in Cancer. J Natl Cancer Inst 1996;88:252–258.

219.

Doci R, Gennari L, Bignami P, Montalto F, Morabito A, Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991;78:797–801.PubMed

220.

Bozzetti F, Doci R, Bignami P, Morabito A, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg 1987;205:264–270.PubMed

221.

Nordlinger B, Quilichini MA, Parc R, Hannoun L, Delva E, Huguet C. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg 1987;205:256–263.PubMed

222.

Butler J, Attiyeh FF, Daly JM. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 1986;162:109–113.PubMed

223.

Wallace S, Carrasco CH, Charnsangavej C, Richli WR, Wright K, Gianturco C. Hepatic artery infusion and chemoembolization in the management of liver metastases. Cardiovasc Intervent Radiol 1990;13:153–160.PubMed

224.

Soulen MC. Chemoembolization of hepatic malignancies. Oncology (Williston Park) 1994;8:77–84; discussion 84, 89–90 passim.

225.

Taniguchi H, Takahashi T, Yamaguchi T, Sawai K. Intraarterial infusion chemotherapy for metastatic liver tumors using multiple anti-cancer agents suspended in a lipid contrast medium. Cancer 1989;64:2001–2006.PubMed

226.

Hunt TM, Flowerdew AD, Birch SJ, Williams JD, Mullee MA, Taylor I. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990;77:779–782.PubMed

227.

Feun LG, Reddy KR, Yrizarry JM, Savaraj N, Guerra JJ, Jr., Purser RK, Waldman S, Levi JU, Moffatt F, Morrell L, et al. A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. Am J Clin Oncol 1994;17:405–410.PubMed

228.

Kameyama M, Imaoka S, Fukuda I, Nakamori S, Sasaki Y, Fujita M, Hasegawa Y, Iwanaga T. Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastasis of colorectal cancer. Surgery 1993;114:97–101.PubMed

229.

Tellez C, Benson AB, III, Lyster MT, Talamonti M, Shaw J, Braun MA, Nemcek AA, Jr., Vogelzang RL. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82:1250–1259.PubMed

230.

Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 2005;32:778–787.PubMed

231.

Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711–1720.PubMed

232.

Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, Madoff DC, Gupta S, Wallace MJ, Ahrar K, Hicks ME. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 2005;16:937–945.PubMed

233.

Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13:S223–S229.PubMed

234.

Jaeck D, Bachellier P, Weber JC, Mourad M, Walf P, Boudjema K. Surgical treatment of synchronous hepatic metastases of colorectal cancers. Simultaneous or delayed resection? Ann Chir 1996;50:507–512; discussion 513–506.PubMed

235.

Fujita S, Akasu T, Moriya Y. Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol 2000;30:7–11.PubMed

236.

Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo R, Jarnagin W, Blumgart L. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197:233–241; discussion 241–232.PubMed

237.

Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 2001;78:17–21.PubMed

238.

Elias D, Detroz B, Lasser P, Plaud B, Jerbi G. Is simultaneous hepatectomy and intestinal anastomosis safe? Am J Surg 1995;169:254–260.PubMed

239.

Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG, Nagorney DM. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum 2004;47:1310–1316.PubMed

240.

Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, Bengmark S. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987;11:541–547.PubMed

241.

Lange JF, Leese T, Castaing D, Bismuth H. Repeat hepatectomy for recurrent malignant tumors of the liver. Surg Gynecol Obstet 1989;169:119–126.PubMed

242.

Stone MD, Cady B, Jenkins RL, McDermott WV, Steele GD, Jr. Surgical therapy for recurrent liver metastases from colorectal cancer. Arch Surg 1990;125:718–721; discussion 722.PubMed

243.

Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, Majno P, Engerran L. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997;225:51–60; discussion 60–52.PubMed

244.

Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002;235:863–871.PubMed

245.

Fernandez-Trigo V, Shamsa F, Sugarbaker PH. Repeat liver resections from colorectal metastasis. Repeat Hepatic Metastases Registry. Surgery 1995;117:296–304.PubMed

246.

Nagakura S, Shirai Y, Yamato Y, Yokoyama N, Suda T, Hatakeyama K. Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001;193:153–160.PubMed

247.

Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, Pignon JP, Ducreux M. Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004;11:274–280.PubMed

248.

Ferrero A, Polastri R, Muratore A, Zorzi D, Capussotti L. Extensive resections for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2004;11:92–96.PubMed

249.

Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003;90:567–574.PubMed

250.

Inoue M, Kotake Y, Nakagawa K, Fujiwara K, Fukuhara K, Yasumitsu T. Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000;70:380–383.PubMed

251.

McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992;53:780–785; discussion 785–786.PubMed

252.

Sakamoto T, Tsubota N, Iwanaga K, Yuki T, Matsuoka H, Yoshimura M. Pulmonary resection for metastases from colorectal cancer. Chest 2001;119:1069–1072.PubMed

253.

Mansel JK, Zinsmeister AR, Pairolero PC, Jett JR. Pulmonary resection of metastatic colorectal adenocarcinoma. A ten year experience. Chest 1986;89:109–112.PubMed

254.

Inoue M, Ohta M, Iuchi K, Matsumura A, Ideguchi K, Yasumitsu T, Nakagawa K, Fukuhara K, Maeda H, Takeda S, Minami M, Ohno Y, Matsuda H. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004;78:238–244.PubMed

255.

Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438–447; discussion 447–450.PubMed

256.

Koehne C, Van Cutsem E, Wils J. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group Study 40986. Proc Am Soc Clin Oncol 2003;22:254a.

Titel: Surgical Therapy for Colorectal Metastases to the Liver
verfasst von: Timothy M. Pawlik
Michael A. Choti
Publikationsdatum: 01.08.2007
Verlag: Springer-Verlag
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 8/2007
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-006-0061-3

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2007

Inferior Vena Cava Stenting: A Safe and Effective Treatment for Intractable Ascites in Patients with Polycystic Liver Disease

A Curative Resection Improves the Postoperative Survival Rate Even in Patients with Advanced Gallbladder Carcinoma

Modified Jejunoileal Bypass Surgery with Biliary Diversion for Morbid Obesity and Changes in Liver Histology During Follow-up

Gallstones Containing Bacteria are Biofilms: Bacterial Slime Production and Ability to Form Pigment Solids Determines Infection Severity and Bacteremia

Hyperbaric Oxygen Therapy Reduces Severity and Improves Survival in Severe Acute Pancreatitis

Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy

Update Chirurgie